NCT04459325View on ClinicalTrials.gov

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

PHASE3CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

July 20, 2020

Study Completion Date

July 20, 2020

Conditions
COVID-19Coronavirus Disease 2019
Interventions
BIOLOGICAL

Tigerase® and best available care

Nebulised dornase alfa \[2.5 mg BID\] for 7 days

OTHER

Best available care

Patients will receive the usual care in accordance with good practice.

Trial Locations (6)

111539

City Clinical Hospital #15, Moscow

119991

I.M. Sechenov First Moscow State Medical University (Sechenov University), Moscow

121309

City Clinical Hospital #51, Moscow

123182

City Clinical Hospital #52, Moscow

129090

N.V. Sklifosovsky Scientific Research Institute of First Aid, Moscow

634050

Siberian State Medical University (SibMed), Moscow

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY

NCT04459325 - Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19 | Biotech Hunter | Biotech Hunter